Stockreport

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results [Yahoo! Finance]

Xilio Therapeutics, Inc.  (XLO) 
PDF Expect to report initial Phase 2 data in microsatellite stable colorectal cancer (MSS CRC) for vilastobart in combination with atezolizumab in the fourth quarter of 202 [Read more]